Kimberly Ferrero

Skip to content Share on Facebook Share on Twitter Share on LinkedIn Share via eMail From utilization to mortality assumptions, these medications raise new cost and risk considerations for actuaries and insurers. By Kimberly Ferrero GLP-1 medications (Glucagon-like peptide-1 receptor agonists) did not begin their clinical lives as weight-loss drugs. Instead, they emerged from efforts in the early 2000s to improve treatment options for people with type 2 diabetes.

Chronic fatigue syndrome (CFS) is characterized as a persistent, debilitating complex disorder of unknown etiology, whereby patients suffer from extreme fatigue, which often presents with symptoms that include chronic pain, depression, weakness, mood disturbances, and neuropsychological impairment. In this mini review and case report, we address central nervous system (CNS) involvement of CFS and present neuropathological autopsy findings from a patient who died with a prior diagnosis of CFS.